UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 1.592

Sortiert nach

Oxaliplatin-based adjuvant chemotherapy duration (3 versus 6 months) for high-risk stage II colon cancer: the randomized phase III ACHIEVE-2 trial

Annals of oncology, 2021-01, Vol.32 (1), p.77-84

2021

Link zum Volltext

Verfügbarkeit prüfen

Stress concentration around an atelectatic region: A finite element model

Respiratory physiology & neurobiology, 2014-09, Vol.201, p.101-110

2014

Link zum Volltext

Verfügbarkeit prüfen

A multicenter retrospective study of gemcitabine plus nab-paclitaxel or FOLFIRINOX in metastatic pancreatic cancer: NAPOLEON study

Annals of oncology, 2019-07, Vol.30, p.iv17-iv18

2019

Link zum Volltext

Verfügbarkeit prüfen

P-171The impact on survival of CPT-11 as third-line or later treatment in advanced gastric cancer

Annals of oncology, 2016-06, Vol.27 (suppl_2), p.ii51-ii51

2016

Link zum Volltext

Verfügbarkeit prüfen

Randomized phase II study of FOLFIRI plus ramucirumab (Rmab) versus FOLFOXIRI plus Rmab as first-line treatment for patients with metastatic colorectal cancer (mCRC): WJOG9216G

Annals of oncology, 2018-10, Vol.29, p.viii201-viii201

2018

Link zum Volltext

Verfügbarkeit prüfen

Updated analysis of a phase II study of SOX plus trastuzumab for the patients with HER2 positive advanced or recurrent gastric cancer: KSCC/HGCSG/CCOG/PerSeUS1501B

Annals of oncology, 2018-10, Vol.29, p.viii225-viii225

2018

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of a recombinant soluble human thrombomodulin (ART-123) in preventing oxaliplatin induced peripheral neuropathy (OIPN): Results of a placebo-controlled, randomized, double-blind phase II study

Annals of oncology, 2018-10, Vol.29, p.viii199-viii199

2018

Link zum Volltext

Verfügbarkeit prüfen

Initial report of a phase I/II study of S-1 and irinotecan (IRIS) in combination with cetuximab in patients with wild-type RAS metastatic colorectal cancer

Annals of oncology, 2018-10, Vol.29 Suppl 8, p.viii166

2018

Link zum Volltext

Verfügbarkeit prüfen

Phase II study of S-1 and oxaliplatin as neo-adjuvant chemotherapy for locally advanced gastric and esophago-gastric cancer (KSCC1601)

Annals of oncology, 2018-10, Vol.29, p.viii225-viii226

2018

Link zum Volltext

Verfügbarkeit prüfen

A phase I/II study of panitumumab combined with TAS-102 in patients (pts) with RAS wild-type (wt) metastatic colorectal cancer (mCRC) refractory to standard chemotherapy: APOLLON study

Annals of oncology, 2018-06, Vol.29, p.v71-v71

2018

Link zum Volltext

Verfügbarkeit prüfen

Phase II study of trifluridine/tipiracil plus bevacizumab by RAS mutation status in patients with metastatic colorectal cancer refractory to standard therapies: JFMC51-1702-C7

ESMO open, 2021-04, Vol.6 (2), p.100093-100093, Article 100093

2021

Link zum Volltext

Verfügbarkeit prüfen

A phase II study to explore biomarkers for the use of mFOLFOX6/XELOX plus bevacizumab as a first-line chemotherapy in patients with metastatic colorectal cancer (WJOG7612GTR)

ESMO open, 2022-12, Vol.7 (6), p.100592, Article 100592

2022

Link zum Volltext

Verfügbarkeit prüfen

Analysis of crack growth in a 3D Voronoi structure: a model for fatigue in low density trabecular bone

Journal of biomechanical engineering, 2002-10, Vol.124 (5), p.512

2002

Link zum Volltext

Verfügbarkeit prüfen

The digital trade oversight

International trade forum, 2017-06, Vol.2017 (2), p.10-11

Lee-Makiyama, Hosuk

2017

Link zum Volltext

Verfügbarkeit prüfen

Natural Course of Asymptomatic Hepatitis C Virus–Infected Patients and Hepatocellular Carcinoma After Interferon Therapy

Clinical gastroenterology and hepatology, 2005-10, Vol.3 (10 Suppl 2), p.S89-S91

2005

Link zum Volltext

Verfügbarkeit prüfen

1513MO A phase II study of nivolumab plus low dose ipilimumab as first -line therapy in patients with advanced gastric or esophago-gastric junction MSI-H tumor: First results of the NO LIMIT study (WJOG13320G/CA209-7W7)

Annals of oncology, 2023-10, Vol.34, p.S852-S853

2023

Link zum Volltext

Verfügbarkeit prüfen

482P Blood-based oxidative phosphorylation-related gene signature and their SNPs as novel prognostic biomarkers for gastric cancer patients treated with nivolumab

Annals of oncology, 2024-06, Vol.35, p.S192-S192

2024

Link zum Volltext

Verfügbarkeit prüfen

486P Genomic profile differences between primary and recurrent tumors in curatively resected gastric cancer: The Liquid-GEAR study

Annals of oncology, 2024-06, Vol.35, p.S193-S194

2024

Link zum Volltext

Verfügbarkeit prüfen

P028 A pathogenic role of activated mucosal-associated invariant T cells in an animal model of Inflammatory Bowel Disease

Journal of Crohn's and colitis, 2024-01, Vol.18 (Supplement_1), p.i284-i284

2024

Link zum Volltext

Verfügbarkeit prüfen

149P A prospective observational study of MSI screening in unresectable chemotherapy-naïve advanced gastric cancer/gastroesophageal junction cancer: WJOG13320GPS

Annals of oncology, 2023-11, Vol.34, p.S1532-S1533

2023

Link zum Volltext

Verfügbarkeit prüfen

454P A multicenter randomized open-label phase II study investigating optimal antiemetic therapy for patients with advanced/recurrent gastric cancer treated with trastuzumab deruxtecan (T-DXd): EN-hance study

Annals of oncology, 2023-11, Vol.34, p.S1639-S1640

2023

Link zum Volltext

Verfügbarkeit prüfen

1547P SNP discovery based on transcriptome sequencing of whole blood RNA to find predictive biomarkers for nivolumab in gastric cancer

Annals of oncology, 2023-10, Vol.34, p.S868-S868

2023

Link zum Volltext

Verfügbarkeit prüfen

1549P A prospective study of circulating tumor DNA (ctDNA) genomic profiling in gastric or gastroesophageal junction (GEJ) cancer patients with recurrence after adjuvant chemotherapy: Liquid-GEAR trial

Annals of oncology, 2023-10, Vol.34, p.S868-S869

2023

Link zum Volltext

Verfügbarkeit prüfen

323P Five-year efficacy and safety in a randomized phase III trial investigating duration of adjuvant oxaliplatin-based therapy (3- vs. 6-months) for patients with high-risk stage II colon cancer: ACHIEVE-2 trial

Annals of oncology, 2022-09, Vol.33, p.S686

2022

Link zum Volltext

Verfügbarkeit prüfen

1259TiP Investigator-initiated phase II study of nivolumab plus low-dose ipilimumab as first-line therapy for microsatellite instability—high advanced gastric or esophagogastric junction cancer (NO LIMIT, WJOG13320G/CA209-7W7)

Annals of oncology, 2022-09, Vol.33, p.S1123

2022

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 1.592

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.158)
Mit Volltextzugriff
(1.411)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(708)
Life Sciences & Biomedicine
(582)
Humans
(541)
Male
(363)
Female
(306)
Middle Aged
(239)
Aged
(217)
Adult
(207)
Oncology
(135)
Cardiovascular System & Cardiology
(134)
Cardiac & Cardiovascular Systems
(123)
Mutation
(87)
Patients
(87)
Technology
(86)
Retrospective Studies
(85)
Biological And Medical Sciences
(82)
Medical Sciences
(79)
Aged, 80 And Over
(77)
Animals
(76)
Medicine
(73)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(6)
... seit 90 Tagen
(11)

Menü

Weitere Dienste

Einstellungen

Oxaliplatin-based adjuvant chemotherapy duration (3 versus 6 months) for high-risk stage II colon cancer: the randomized phase III ACHIEVE-2 trial

Stress concentration around an atelectatic region: A finite element model

A multicenter retrospective study of gemcitabine plus nab-paclitaxel or FOLFIRINOX in metastatic pancreatic cancer: NAPOLEON study

P-171The impact on survival of CPT-11 as third-line or later treatment in advanced gastric cancer

Randomized phase II study of FOLFIRI plus ramucirumab (Rmab) versus FOLFOXIRI plus Rmab as first-line treatment for patients with metastatic colorectal cancer (mCRC): WJOG9216G

Updated analysis of a phase II study of SOX plus trastuzumab for the patients with HER2 positive advanced or recurrent gastric cancer: KSCC/HGCSG/CCOG/PerSeUS1501B

Efficacy and safety of a recombinant soluble human thrombomodulin (ART-123) in preventing oxaliplatin induced peripheral neuropathy (OIPN): Results of a placebo-controlled, randomized, double-blind phase II study

Initial report of a phase I/II study of S-1 and irinotecan (IRIS) in combination with cetuximab in patients with wild-type RAS metastatic colorectal cancer

Phase II study of S-1 and oxaliplatin as neo-adjuvant chemotherapy for locally advanced gastric and esophago-gastric cancer (KSCC1601)

A phase I/II study of panitumumab combined with TAS-102 in patients (pts) with RAS wild-type (wt) metastatic colorectal cancer (mCRC) refractory to standard chemotherapy: APOLLON study

Phase II study of trifluridine/tipiracil plus bevacizumab by RAS mutation status in patients with metastatic colorectal cancer refractory to standard therapies: JFMC51-1702-C7

A phase II study to explore biomarkers for the use of mFOLFOX6/XELOX plus bevacizumab as a first-line chemotherapy in patients with metastatic colorectal cancer (WJOG7612GTR)

Analysis of crack growth in a 3D Voronoi structure: a model for fatigue in low density trabecular bone

The digital trade oversight

Natural Course of Asymptomatic Hepatitis C Virus–Infected Patients and Hepatocellular Carcinoma After Interferon Therapy

1513MO A phase II study of nivolumab plus low dose ipilimumab as first -line therapy in patients with advanced gastric or esophago-gastric junction MSI-H tumor: First results of the NO LIMIT study (WJOG13320G/CA209-7W7)

482P Blood-based oxidative phosphorylation-related gene signature and their SNPs as novel prognostic biomarkers for gastric cancer patients treated with nivolumab

486P Genomic profile differences between primary and recurrent tumors in curatively resected gastric cancer: The Liquid-GEAR study

P028 A pathogenic role of activated mucosal-associated invariant T cells in an animal model of Inflammatory Bowel Disease

149P A prospective observational study of MSI screening in unresectable chemotherapy-naïve advanced gastric cancer/gastroesophageal junction cancer: WJOG13320GPS

454P A multicenter randomized open-label phase II study investigating optimal antiemetic therapy for patients with advanced/recurrent gastric cancer treated with trastuzumab deruxtecan (T-DXd): EN-hance study

1547P SNP discovery based on transcriptome sequencing of whole blood RNA to find predictive biomarkers for nivolumab in gastric cancer

1549P A prospective study of circulating tumor DNA (ctDNA) genomic profiling in gastric or gastroesophageal junction (GEJ) cancer patients with recurrence after adjuvant chemotherapy: Liquid-GEAR trial

323P Five-year efficacy and safety in a randomized phase III trial investigating duration of adjuvant oxaliplatin-based therapy (3- vs. 6-months) for patients with high-risk stage II colon cancer: ACHIEVE-2 trial

1259TiP Investigator-initiated phase II study of nivolumab plus low-dose ipilimumab as first-line therapy for microsatellite instability—high advanced gastric or esophagogastric junction cancer (NO LIMIT, WJOG13320G/CA209-7W7)

Suchergebnisse filtern